| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
The primary target of Sotetsuflavone is the DENV-NS5 RNA-dependent RNA polymerase (RdRp), a key enzyme in the replication of the dengue virus. It also targets cancer cell migration and invasion pathways. It inhibits the phosphorylation of PI3K, Akt, mTOR, JNK, and p38 MAPK.
|
|---|---|
| ln Vitro |
Sotetsuflavone's inhibitory activity against DENV-NS5 RdRp has been demonstrated in cell-free enzymatic assays. It was identified as the most active compound in a series of biflavonoids, with an IC50 of 0.16 μM. Structure-activity relationship studies showed that the number and position of methyl groups modulate its inhibition of the polymerase. In vitro, Sotetsuflavone inhibits the migration and invasion of A549 lung cancer cells by reversing epithelial-mesenchymal transition (EMT) and induces cell apoptosis and autophagy. It also inhibits the expression of HIF-1α, VEGF, MMP-9, and MMP-13 in A549 cells. It modulates the expression of Cyclin D1, CDK4, Bcl-2, and Bax.
|
| ln Vivo |
Sotetsuflavone has been shown to inhibit tumor growth in vivo. Injection of β,β-Dimethylacrylshikonin combined with IR treatment significantly suppressed tumor growth in an HCT-116 xenograft model. It activates the KATP channel and PDK1-Akt-eNOS pathway.
|
| Enzyme Assay |
Sotetsuflavone is tested in cell-free assays for its ability to inhibit DENV-NS5 RdRp activity. The enzyme is incubated with a RNA template, nucleotides, and the compound. The incorporation of labeled nucleotides is measured to determine the IC50.
|
| Cell Assay |
Cells such as A549 lung cancer cells are treated with Sotetsuflavone. Effects on cell migration (wound healing assay), invasion (transwell assay), apoptosis (flow cytometry), and autophagy (LC3 staining) are evaluated. Protein expression is analyzed by Western blot.
|
| Animal Protocol |
In vivo efficacy is evaluated using xenograft mouse models. Mice bearing tumors are treated with the compound (e.g., by injection), and tumor growth is monitored. Tissue samples are collected for histological and molecular analysis to assess the compound's mechanism of action.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Sotetsuflavone are not well-documented. As a flavonoid, its oral bioavailability may be limited. Its physicochemical properties (LogP 3.41) suggest moderate lipophilicity. Further studies are needed to characterize its absorption and metabolism.
|
| Toxicity/Toxicokinetics |
Toxicological data for Sotetsuflavone is limited. It is generally considered safe for research use. Its anticancer activity suggests it may have cytotoxic effects on cancer cells, but its selectivity and safety profile require further investigation.
|
| References | |
| Additional Infomation |
According to reports, cycad flavonoids are found in yew, selaginella, and other organisms with available data.
Sotetsuflavone is a research compound with potent anti-dengue virus and anticancer activities. It is a valuable tool for studying viral replication and cancer cell biology. It has not been approved for clinical use and is strictly for research purposes. |
| Molecular Formula |
C31H20O10
|
|---|---|
| Molecular Weight |
552.4845
|
| Exact Mass |
552.105
|
| CAS # |
2608-21-1
|
| PubChem CID |
5494868
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
873.1±65.0 °C at 760 mmHg
|
| Flash Point |
293.0±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.750
|
| LogP |
3.41
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
41
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OIFVLHZEBAXHPM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H20O10/c1-39-26-13-23(38)30-22(37)12-24(14-2-5-16(32)6-3-14)41-31(30)28(26)18-8-15(4-7-19(18)34)25-11-21(36)29-20(35)9-17(33)10-27(29)40-25/h2-13,32-35,38H,1H3
|
| Chemical Name |
8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8100 mL | 9.0501 mL | 18.1002 mL | |
| 5 mM | 0.3620 mL | 1.8100 mL | 3.6200 mL | |
| 10 mM | 0.1810 mL | 0.9050 mL | 1.8100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
